Ambry

Agilent Technologies and PerkinElmer have signed an agreement that will see PerkinElmer's Signature Genomics business switch to Agilent arrays for its genetic testing services.

This story has been updated to include comments from a Roche NimbleGen service provider and a Roche spokesperson.

Early adopters of clinical sequencing are all taking slightly different approaches — from whole-genome sequencing to exome sequencing to targeted panels — but one of the key hurdles they all face is interpretation and analysis, according to speakers at Cambridge Healthtech Instit

This article has been updated from a previous version to include market research information about Fluidigm from DeciBio.

This story was originally posted on April 20.

Ambry Genetics said today that it has launched genomic research services based on Fluidigm's BioMark HD and Access Array systems.

Ambry Genetics has launched the First-Step Exome test, a sequencing-based test that analyzes the exons and flanking intronic regions of 4,400 genes that are known to be associated with human disease and are defined within the Human Gene Mutation Database.

Ambry Genetics has launched four targeted sequencing-based cancer panels: CancerNext, BreastNext, ColoNext, and OvaNext.

By Monica Heger
As exome sequencing quickly becomes the method of choice for diagnosing rare conditions, a number of academic groups and companies have launched tests in recent months and are reporting their first successes.

Pages

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.

CNBC reports that there are thousands of genetic tests available for consumers to chose between.

In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.